Search

Your search keyword '"Morlat P."' showing total 1,346 results

Search Constraints

Start Over You searched for: Author "Morlat P." Remove constraint Author: "Morlat P."
1,346 results on '"Morlat P."'

Search Results

2. Bubble Growth Rate in Superheated Droplets

3. Immunovirological status in people with perinatal and adult-acquired HIV-1 infection: a multi-cohort analysis from France

4. Polyvictimization and Depressive Symptomatology in Adolescents: Evaluation of the Role of School Social Climate

5. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection

6. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death

7. The SIMPLE Phase II Dark Matter Search

8. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

9. HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007–12: impact on susceptibility to first-line strategies

10. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

11. Fabrication and Response of High Concentration SIMPLE Superheated Droplet Detectors with Different Liquids

12. Final Analysis and Results of the Phase II SIMPLE Dark Matter Search

13. New limits on WIMP interactions from the SIMPLE dark matter search

14. First Results of the Phase II SIMPLE Dark Matter Search

16. Discrimination of nuclear recoils from alpha particles with superheated liquids

17. Can Light-nuclei Search Experiments Constrain the Spin-independent Dark Matter Phase Space?

18. Heavy Superheated Droplet Detectors as a Probe of Spin-independent WIMP Dark Matter Existence

19. SIMPLE Dark Matter Search Results

20. WIMP searches with superheated droplet detectors: Status and Prospects

21. Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study

27. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

28. Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial

30. Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus‐co‐infected patients (ANRS CO13‐HEPAVIH)

33. Cover Image

34. Efficacy, safety and patient‐reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor‐experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study)

35. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

36. Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course

37. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL

38. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

42. Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort]

43. Differences in HIV cure clinical trial preferences of French people living with HIV and physicians in the ANRS?APSEC study: a discrete choice experiment

45. Levels and determinants of breast and cervical cancer screening uptake in HIV‐infected women compared with the general population in France

46. Post‐HCV cure self‐reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH)

47. Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity

48. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

49. Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy

50. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL

Catalog

Books, media, physical & digital resources